An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 867-881

  De, Pradip ^b   Dey, Nandini ^b   Terakedis, Breanne ^b   Bergsagel, P Leif ^c   Li, Zhi Hua ^d   Mahadevan, Daruka ^e   Garlich, Joseph R ^f   Trudel, Suzanne ^d   Makale, Milan T ^g   Durden, Donald L ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f SignalRx Pharmaceuticals   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

IGF 1; IL 6; Multiple myeloma; Pan PI 3 kinase inhibitor; SF1126

Indexed keywords

[1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; BORTEZOMIB; CASPASE 3; CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P70; S6 KINASE; ANTINEOPLASTIC AGENT; CASPASE; CHROMONE DERIVATIVE; HIF1A PROTEIN, HUMAN; INTEGRIN; OLIGOPEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN STABILITY; TUMOR VASCULARIZATION; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; METABOLISM; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASES; CHROMONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRINS; MICE; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84878884497     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2078-0     Document Type: Article

References (44)

1. Bandi P, Blount L, Boone M, Books D, Calle J, Chen A, Cokkinides V, Conner E, Dahl J, Doroshenck M, Doyle C, Gansler T, Glynn T, Heier EJ, Jacobs E, Jorenson D, Kirch R, Klevan W, Laurie D, McGinnis L, Murray T, Noel D, Rodriguez C, Saslow D, Schmidt C, Shafey O, DeSantis C, Smith R, Stefanek M, Summers S, Teschendorf B, Wang S, Weinstock M, Yates J (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta
2. Laubach J, Richardson P, Anderson K (2011) Multiple myeloma. Annu Rev Med 62:249-264
3. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S et al (2010) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 116:1460-1468
4. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5:221-230 (Pubitemid 38402114)
5. Ishikawa H, Tsuyama N, Obata M, Kawano M (2006) Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas. J Clin Exp Hematop 46:55-66
6. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L (1994) A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367:40-46 (Pubitemid 24038530)
7. Federica C, Antonio P, Guido T, Mario B (2006) Targeting signaling pathways in multiple myeloma. Curr Pharm Biotechnol 7:407-413 (Pubitemid 46017531)
8. Ge NL, Rudikoff S (2000) Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 19:4091-4095
9. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG et al (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107:4053-4062 (Pubitemid 43726814)
10. Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21:6587-6597 (Pubitemid 35177037)
11. Witzig TE, Kaufmann SH (2006) Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7:285-294 (Pubitemid 44043658)
12. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM (2007) Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 13:3771-3775 (Pubitemid 47037580)
13. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B et al (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936-943 (Pubitemid 41294438)
14. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P et al (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 Kinase p110alpha inhibitors. Bioorg Med Chem 14:6847-6858 (Pubitemid 44307656)
15. Workman P (2001) Pharmacokinetics and chemistry of LY294002. Proceeding of the 80th Meeting of American Association for Cancer Research (AACR) 88:105
16. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V et al (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68:206-215 (Pubitemid 351380122)
17. Mahadevan D, Chiorean EG, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F et al (2012) Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer 48:3319-3327
18. Field-Smith A, Morgan GJ, Davies FE (2006) Bortezomib (Velcadetrade mark) in the treatment of Multiple Myeloma. Ther Clin Risk Manag 2:271-279 (Pubitemid 44349502)
19. Gills JJ, Dennis PA (2009) Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 11:102-110
20. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M et al (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 29:4243-4249
21. Holmes D (2011) PI3K pathway inhibitors approach junction. Nat Rev Drug Discov 10:563-564
22. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV (2005) Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 67:4-17 (Pubitemid 41318288)
23. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076 (Pubitemid 32691956)
24. Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20:5991-6000 (Pubitemid 32955041)
25. Martinez-Sanchez G, Giuliani A (2007) Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. J Exp Clin Cancer Res 26:39-50 (Pubitemid 46656031)
26. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239 (Pubitemid 47101660)
27. Zeng L, Kizaka-Kondoh S, Itasaka S, Xie X, Inoue M, Tanimoto K, Shibuya K, Hiraoka M (2007) Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 98:1394-1401 (Pubitemid 47241762)
28. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26(54):7509-7516 (Pubitemid 350207705)
29. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783-791 (Pubitemid 47313207)
30. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK (2006) Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 30:262-265 (Pubitemid 43053219)
31. Jackson RC (2012) Pharmacodynamic modelling of biomarker data in oncology. ISRN Pharmacol 2012:590626
32. Yang M, Huang J, Pan HZ, Jin J (2008) Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3K/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med 22:489-496
33. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S et al (2000) SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 275:27845-27850
34. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S et al (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547-2557
35. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA et al (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116 (Pubitemid 30637735)
36. Su JD, Mayo LD, Donner DB, Durden DL (2003) PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 63:3585-3592 (Pubitemid 36793039)
37. Huang J, Kontos CD (2002) PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J Biol Chem 277:10760-10766 (Pubitemid 34952828)
38. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489 (Pubitemid 34968598)
39. Jiang BH, Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19-65
40. Li J, Li F, Wang H, Wang X, Jiang Y, Li D (2012) Wortmannin reduces metastasis and angiogenesis of human breast cancer cells via nuclear factor-kappaB-dependent matrix metalloproteinase-9 and interleukin-8 pathways. J Int Med Res 40:867-876
41. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN et al (2006) The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 103:19478-19483 (Pubitemid 46026056)
42. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12:363-369 (Pubitemid 32685637)
43. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R (2007) Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 100:79-87 (Pubitemid 46066776)
44. Chipuk JE, Green DR (2006) Dissecting p53-dependent apoptosis. Cell Death Differ 13:994-1002